Form 4: uniQure Director Trades Ordinary Shares

uniQure N.V. Director Jack Kaye reports transactions involving the purchase and sale of ordinary shares, executed under a Rule 10b5-1 trading plan.

Summary

• Director Jack Kaye of uniQure N.V. engaged in several transactions involving the company's ordinary shares on June 30, 2026.
• These transactions included the purchase of 4,107 ordinary shares at $37.00 per share and another purchase of 17,060 ordinary shares at $20.18 per share.
• Concurrently, Mr. Kaye sold 4,107 ordinary shares at a weighted average price of $46.49 and 17,060 ordinary shares at a weighted average price of $46.43.
• The sales were executed under a pre-arranged trading plan adopted on June 16, 2025, designed to comply with Rule 10b5-1(c) of the Securities Exchange Act of 1934.
• Following these transactions, Mr. Kaye beneficially owns 25,996 ordinary shares directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. While insider sales can be a negative signal, the execution under a Rule 10b5-1 plan mitigates concerns about opportunistic trading, and the purchases suggest continued director confidence.

Positives

• The transactions were conducted under a Rule 10b5-1 plan, indicating adherence to established compliance procedures for insider trading.
• The purchases suggest a continued belief in the company's value by a director, with shares acquired at prices significantly lower than the sale prices.
• The sales were executed at prices ranging from $46.19 to $46.88, indicating a favorable market price at the time of sale.

Negatives

• A significant number of shares were sold by a director, which could be interpreted negatively by the market, despite being part of a pre-planned strategy.
• The weighted average sale price of $46.49 and $46.43 is notably higher than the purchase prices of $37.00 and $20.18, indicating a profit-taking scenario.

Risks

• Market perception of insider selling, even if pre-planned, can negatively impact stock price.
• The company's performance and future prospects, which underpin the share price, remain subject to the inherent risks of the biotechnology sector.

Future Outlook

The filing itself does not contain forward-looking statements or guidance. The transactions are historical events executed under a pre-defined plan.

Management Comments

• The transactions reported herein were effected pursuant to a sales plan adopted by the Reporting Person on June 16, 2025 and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934.
• The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $46.19 to $46.88.
• The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in the footnote.

Industry Context

StockSavvy.ai notes that insider transactions, particularly sales, are closely watched by investors. The execution of these trades under a Rule 10b5-1 plan is a standard practice to mitigate concerns about insider trading, but the volume and timing can still influence market sentiment in the gene therapy sector, which is characterized by high R&D costs and regulatory hurdles.

Stakeholder Impact

• Shareholders: May interpret the director's sales as a signal, potentially leading to short-term price fluctuations, though the Rule 10b5-1 plan provides a mitigating context.
• Management: The transactions reflect standard personal financial planning for executives in publicly traded companies.
• Employees: Similar to shareholders, employees holding stock options or shares may react to insider selling signals.

Next Steps

• Continued monitoring of insider trading activity for any further transactions.
• Evaluation of uniQure's ongoing clinical trial progress and regulatory milestones.

Key Dates

Keywords

uniQure, QURE, Form 4, Insider Trading, Rule 10b5-1, Director Transactions, Ordinary Shares, Securities Exchange Act, Beneficial Ownership